Kengreal (Cangrelor Tetrasodium) Patent Expiration, LOE Window & CMS Spending

Kengreal (Cangrelor Tetrasodium) by Chiesi Usa: FDA Orange Book LOE 2035-07-10, 0 AB generics, $171K 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Usa
FDA Application & PathwayN204958 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-07-10
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$171K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$171K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.2% 2-yr change)